Effects of clazosentan, cilostazol, and statins on aneurysmal subarachnoid hemorrhage : A protocol for systematic review and meta-analysis

BACKGROUND: Aneurysmal subarachnoid hemorrhage (aSAH) is a disease caused by the infiltration of blood into the subarachnoid space due to the rupture of an intracranial aneurysm. It is a serious cerebrovascular disease, with a mortality rate of about 40% worldwide, which seriously threatens human life and health. Many drugs are used to treat aSAH and its complications, and some have been tested in systematic reviews and have shown good effects. But which drug has the best effect remains unclear. This network meta-analysis (NMA) aims to assess the effectiveness and feasibility of clazosentan, cilostazol, and statins in patients with aSAH.

METHODS: We will search for EMBASE.com, PubMed, the Cochrane Library, and Web of Science from inception to December 2019. Randomized controlled trials (RCTs) reporting efficacy and safety of clazosentan, cilostazol, and statins compared with the control, or compared with each other for the treatment of aSAH will be included. Two independent reviewers will assess the risk of bias of the included RCTs with the Cochrane "Risk of bias" tool. The pairwise meta-analysis will be performed with the random-effects model. The NMA will be performed in a Bayesian hierarchical framework using Markov Chain Monte Carlo method in WinBUGS 1.4.3. Egger test and funnel plot will be used to assess the publication bias. We will evaluate the quality of evidence for each outcome according to the GRADE approach.

RESULTS: The results of this NMA will be submitted to a peer-reviewed journal for publication.

CONCLUSION: This study will summarize up-to-date evidence to compare the efficacy and safety of clazosentan, cilostazol, and statins on aSAH.PROSPERO registration number: CRD42019147523.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:99

Enthalten in:

Medicine - 99(2020), 17 vom: 01. Apr., Seite e19902

Sprache:

Englisch

Beteiligte Personen:

He, Junfang [VerfasserIn]
Zhang, Li [VerfasserIn]
Yu, Yao [VerfasserIn]
Luo, Xinyue [VerfasserIn]
Wei, Min [VerfasserIn]
Chen, Gen [VerfasserIn]
Shen, Yanfei [VerfasserIn]

Links:

Volltext

Themen:

3DRR0X4728
Cilostazol
Clazosentan
Dioxanes
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Journal Article
N7Z035406B
Pyridines
Pyrimidines
Sulfonamides
Tetrazoles

Anmerkungen:

Date Completed 11.05.2020

Date Revised 15.01.2021

published: Print

Citation Status MEDLINE

doi:

10.1097/MD.0000000000019902

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM309168155